Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, 16 March 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in March. Both sponsored research analysts commented on the recently announced rights issue and MucoVax collaboration. Analysguiden reduced its price target to SEK 12 per share, primarily a result of dilution from the rights issue and updates to its estimates for ABNCoV2, the COVID-19 vaccine candidate.
The Analysguiden report dives deeper into recent topics related to the COVID-19 vaccine, including upcoming milestones, the 26 January 2023 FDA advisory committee meeting, Bavarian Nordic's expected payments to ExpreS[2]ion associated company and partner in the COVID-19 vaccine, AdaptVac, and vaccination trends. Furthermore, Analyst Sten Westerberg comments on the rights issue (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-a-rights-issue-of-units-of-approximately-sek-102-4-million,c3727460), recently formed infectious diseases advisory board (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-formation-of-infectious-diseases-scientific-advisory-board,c3730060), and recently announced mucosal vaccine program (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-grant-award-for-the-development-of-new-platforms-for-universal-mucosal-vaccines,c3723847).
The research reports are available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB